Jim Hollingshead - ResMed Insider

ResMed Inc -- USA Stock  

USD 88.79  0.06  0.0676%

President - Americas

Dr. Jim Hollingshead, Ph.D. is President Sleep Business of the Company. Mr. Hollingshead joined ResMed in March 2010 as vice president of strategy and business development. In August 2011, his role was expanded to include the leadership of ResMed ventures and initiatives, the unit responsible for growing early stage businesses. In March 2013, he was appointed president Americas. Before joining us, Mr. Hollingshead spent 18 years in strategy consulting, where he worked with senior executives across a wide range of industries. From September 2008 to February 2010, he was a senior partner in the strategy and life sciences practices at Deloitte Consulting, based in San Francisco. Before that Mr. Hollingshead was managing partner, west coast for Monitor Group, a global strategy consulting firm. While at Monitor Group, Mr. Hollingshead worked in various offices around the world, and successfully launched and ran three different practices, including a panEuropean marketing strategy practice based in London
Age: 53  President Since 2017  Ph.D    
858 836-5000  www.resmed.com
Hollingshead holds an A.B. in history and international relations with highest distinction from Stanford University, and an M.A. and Ph.D in political science from the University of California at Berkeley, where he was awarded a graduate student fellowship by the National Science Foundation.

Management Efficiency

The company has Return on Asset of 8.72 % which means that on every $100 spent on asset it made $8.72 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 18.43 % implying that it generated $18.43 on every 100 dollars invested.
The company has 1.02 B in debt with debt to equity (D/E) ratio of 49.7 . This implies that the company may be unable to create cash to meet all of its financial commitments. ResMed Inc has Current Ratio of 4.63 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Eric ThepautBoston Scientific Corporation
2015
Lanny RoperDexCom Inc
2015
Ulrich MichelDENTSPLY SIRONA Inc
2016
Michael PrevoznikQuest Diagnostics Incorporated
2003
Wendy CarruthersBoston Scientific Corporation
2012
Jeffrey MirvissBoston Scientific Corporation
2013
Andrew BaloDexCom Inc
2015
Michael PhalenBoston Scientific Corporation
2012
Deborah RasinDENTSPLY SIRONA Inc
2011
Nicholas AlexosDENTSPLY SIRONA Inc
2017
Karen PrangeBoston Scientific Corporation
2012
Keith DawkinsBoston Scientific Corporation
2012
Everett CunninghamQuest Diagnostics Incorporated
2012
Rainer BerthanDENTSPLY SIRONA Inc
2016
Jonathan FriedmanDENTSPLY SIRONA Inc
2016
Donald AbbeyDexCom Inc
2017
David PierceBoston Scientific Corporation
2016
Albert SterkenburgDENTSPLY SIRONA Inc
2009
Albert WhiteThe Cooper Companies Inc
2016
John SorensonBoston Scientific Corporation
2014
Jeffrey MoyDexCom Inc
2011

Entity Summary

ResMed Inc. designs, develops, manufactures, and markets medical devices and cloudbased software applications that diagnose, treat, and manage respiratory disorders. ResMed Inc (RMD) is traded on New York Stock Exchange in USA. It is located in CALIFORNIA, U.S.A and employs 5,250 people. ResMed is listed under Medical Equipment category by Fama And French industry classification.

Did you try this?

Run Focused Opportunities Now
   

Focused Opportunities

Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Hide  View All  NextLaunch Focused Opportunities
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add ResMed Inc to your portfolio

Top Management

ResMed Inc Leadership Team
John Wareham, Director, MBA
Ronald Taylor, Director
Gary Pace, Director, Ph.D
Agnes Lee, Director
Carol Burt, Director
Rich Sulpizio, Director
Peter Farrell, Chairman, Ph.D
Jim Hollingshead, President, Ph.D
Don Darkin, President
Jack Wareham, Director
Anne Reiser, President
Karen Drexler, Director
Richard McHale, President
Donald Darkin, President
Rob Douglas, President
Christopher Roberts, Director, MBA
Chris Roberts, Director, MBA
Robert Douglas, COO
BE Farrell, Chairman
Brett Sandercock, CFO
Ron Taylor, Director
Raj Sodhi, President, MBA
David Pendarvis, Executive
Richard Sulpizio, Director
Michael Farrell, CEO, MBA

Stock Performance

ResMed Performance Indicators